Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Opus Genetics (Nasdaq: IRD), a clinical-stage biopharmaceutical company focused on gene therapies for inherited retinal diseases, has granted equity inducement awards to two new non-executive employees on June 30, 2025. The awards include 240,000 stock options at an exercise price of $0.94 per share and 150,000 restricted stock units (RSUs).
The stock options will vest over four years, with 25% vesting after one year and the remaining 75% vesting quarterly thereafter. The RSUs will vest in four equal annual installments. These awards were granted under the Company's 2021 Inducement Plan and approved by the Compensation Committee in compliance with Nasdaq Listing Rule 5635(c)(4).
Opus Genetics (Nasdaq: IRD), una società biofarmaceutica in fase clinica specializzata in terapie geniche per malattie ereditarie della retina, ha assegnato premi azionari di incentivo a due nuovi dipendenti non esecutivi il 30 giugno 2025. I premi comprendono 240.000 opzioni su azioni con un prezzo di esercizio di 0,94 $ per azione e 150.000 unità azionarie vincolate (RSU).
Le opzioni azionarie matureranno in quattro anni, con il 25% che matura dopo un anno e il restante 75% che matura trimestralmente. Le RSU matureranno in quattro rate annuali uguali. Questi premi sono stati concessi nell'ambito del Piano di Incentivo 2021 della Società e approvati dal Comitato per la Retribuzione in conformità con la Regola 5635(c)(4) del Nasdaq.
Opus Genetics (Nasdaq: IRD), una compañía biofarmacéutica en etapa clínica enfocada en terapias génicas para enfermedades hereditarias de la retina, ha otorgado premios de incentivos accionarios a dos nuevos empleados no ejecutivos el 30 de junio de 2025. Los premios incluyen 240,000 opciones sobre acciones con un precio de ejercicio de $0.94 por acción y 150,000 unidades restringidas de acciones (RSU).
Las opciones sobre acciones se consolidarán a lo largo de cuatro años, con un 25% consolidándose después de un año y el 75% restante consolidándose trimestralmente. Las RSU se consolidarán en cuatro cuotas anuales iguales. Estos premios fueron otorgados bajo el Plan de Incentivos 2021 de la Compañía y aprobados por el Comité de Compensación en cumplimiento con la Regla 5635(c)(4) de Nasdaq.
Opus Genetics (나스닥: IRD)는 유전성 망막 질환을 위한 유전자 치료에 중점을 둔 임상 단계의 바이오제약 회사로, 2025년 6월 30일에 두 명의 새로운 비임원 직원에게 주식 인센티브를 부여했습니다. 이번 인센티브에는 주당 행사 가격이 $0.94인 240,000주 스톡 옵션과 150,000개의 제한 주식 단위(RSU)가 포함됩니다.
스톡 옵션은 4년에 걸쳐 권리가 부여되며, 1년 후 25%가 부여되고 나머지 75%는 분기별로 부여됩니다. RSU는 4년에 걸쳐 연간 동일한 4회 분할로 부여됩니다. 이 인센티브는 회사의 2021년 유인 계획에 따라 부여되었으며, 나스닥 상장 규칙 5635(c)(4)를 준수하여 보상 위원회의 승인을 받았습니다.
Opus Genetics (Nasdaq : IRD), une société biopharmaceutique en phase clinique spécialisée dans les thérapies géniques pour les maladies héréditaires de la rétine, a accordé des récompenses d'incitation en actions à deux nouveaux employés non exécutifs le 30 juin 2025. Ces récompenses comprennent 240 000 options d'achat d'actions à un prix d'exercice de 0,94 $ par action et 150 000 unités d'actions restreintes (RSU).
Les options d'achat d'actions seront acquises sur une période de quatre ans, avec 25 % acquis après un an et les 75 % restants acquis trimestriellement par la suite. Les RSU seront acquises en quatre versements annuels égaux. Ces récompenses ont été accordées dans le cadre du Plan d'Incitation 2021 de la Société et approuvées par le Comité de Rémunération conformément à la règle 5635(c)(4) du Nasdaq.
Opus Genetics (Nasdaq: IRD), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Gentherapien für vererbte Netzhauterkrankungen spezialisiert hat, hat am 30. Juni 2025 zwei neuen nicht geschäftsführenden Mitarbeitern Aktienanreize gewährt. Die Auszeichnungen umfassen 240.000 Aktienoptionen zu einem Ausübungspreis von 0,94 $ pro Aktie sowie 150.000 Restricted Stock Units (RSUs).
Die Aktienoptionen werden über vier Jahre erworben, wobei 25 % nach einem Jahr und die restlichen 75 % anschließend vierteljährlich vesten. Die RSUs werden in vier gleichen jährlichen Raten vesten. Diese Auszeichnungen wurden im Rahmen des Inducement Plans 2021 des Unternehmens gewährt und vom Vergütungsausschuss gemäß der Nasdaq-Listing-Regel 5635(c)(4) genehmigt.
- None.
- None.
RESEARCH TRIANGLE PARK, N.C., July 03, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders (the “Company”), today announced that, on June 30, 2025, it granted equity awards to two new non-executive employees as a material inducement to employment. The equity awards were granted under the Company’s 2021 Inducement Plan, as amended, and were approved by the Compensation Committee of the Company’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4).
The equity awards consisted of stock options to purchase an aggregate of 240,000 shares of the Company’s common stock and 150,000 restricted stock units (“RSUs”). The stock options have an exercise price of
About Opus Genetics
The Company is a clinical-stage biopharmaceutical company developing gene and small molecule therapies for vision-threatening eye diseases. The Company’s pipeline features AAV-based gene therapies targeting inherited retinal diseases including Leber congenital amaurosis (LCA), bestrophinopathy, and retinitis pigmentosa. Its lead candidate, OPGx-LCA5, is in a Phase 1/2 trial for LCA5-related mutations and has shown encouraging early results. Additional programs include OPGx-BEST1, a gene therapy targeting BEST1-related retinal degeneration and a Phase 3-ready small molecule therapy for diabetic retinopathy, developed under a Special Protocol Assessment with the FDA. The Company is also advancing Phentolamine Ophthalmic Solution
Contacts
Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
ir@opusgtx.com
Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
Source: Opus Genetics, Inc.
FAQ
What equity awards did Opus Genetics (IRD) grant to new employees in June 2025?
What is the vesting schedule for Opus Genetics (IRD) stock options granted in June 2025?
How do the RSUs vest in Opus Genetics' (IRD) June 2025 inducement grants?
What was the exercise price for Opus Genetics' (IRD) stock options granted on June 30, 2025?
